FindTrial
Sign In

Compassionate Use of Pozelimab

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05232110
Enrollment
Unknown
Registered
2022-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD55-deficient Protein-losing Enteropathy

Keywords

Complement Hyperactivation, Angiopathic thrombosis, Protein-Losing Enteropathy (CHAPLE disease)

Brief summary

Provide compassionate use of pozelimab

Detailed description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Interventions

DRUGPozelimab

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026